Clin Gastroenterology H: Anxiety and depression can cause patients with inflammatory bowel disease to stop using anti-tumor necrosis factor drugs

Anti-tumor necrosis factor (anti-TNFs) is a very effective biological agent for the treatment of moderate to severe inflammatory bowel disease (IBD)
.
However, many users of anti-tumor necrosis factor will not respond or fail to respond to treatment later.

Researchers collected IBD patients who used anti-TNF drugs from 2001 to 2016, and then used survival analysis to assess AMD and anti-TNF withdrawal and first occurrence of IBD-related adverse results (adverse results include: IBD-related hospitalization or surgery, new or repeated Use corticosteroids and switch to alternative anti-TNF drugs)
.
Finally, a Cox proportional hazards multivariate regression model was used to adjust the demographic and clinical factors related to the outcome

A total of 1135 IBD patients who started anti-TNF therapy were identified in this study; 178 (15.
7%) of these patients met the diagnostic criteria for AMD
.
The results of the study showed that AMD significantly increased the risk of stopping anti-TNF therapy (OR, 1.

Figure: Time to disease recurrence after stopping anti-tumor necrosis factor

This study confirms that compared with IBD patients without AMD, patients with IBD and AMD within 2 years before starting anti-TNF therapy have a significantly higher risk of stopping anti-tumor necrosis factor therapy.
Therefore, doctors should pay more attention to patients' health in clinical work.
Mental health issues
.

Original source:

Casandra Dolovich.